查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1865485

全球自体免疫疾病药物市场：预测至2032年－按药物类别、适应症、给药途径、通路、最终用户和地区进行分析

Autoimmune Disease Therapeutics Market Forecasts to 2032 - Global Analysis By Drug Class (Immunosuppressants, Anti-inflammatory Drugs, Corticosteroids and Biosimilars), Indication, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的一项研究，预计到 2025 年，全球自体免疫疾病治疗市场价值将达到 71 亿美元，到 2032 年将达到 136 亿美元，在预测期内的复合年增长率为 9.6%。

自体免疫疾病治疗方法旨在治疗和缓解免疫系统错误攻击自身健康组织的疾病。这些药物旨在抑制异常免疫反应、减轻发炎并防止进一步的组织损伤。这些药物包括皮质类固醇、免疫抑制剂、生技药品和标靶治疗，后者可调节特定的免疫路径。自体免疫疾病药物用于治疗类风湿性关节炎、全身性红斑性狼疮、多发性硬化症和发炎性肠道疾病等疾病。目前的研究和开发重点在于开发更安全、更有效、更个人化的治疗方法，以在不损害身体抵抗感染疾病能力的前提下恢復免疫平衡。

疾病盛行率和诊断率不断上升

由于遗传易感性、环境诱因和生活方式因素，自体免疫疾病在全球范围内呈上升趋势。目前已有成熟的平台可用于辅助免疫调节、症状管理和疾病进展管理，这些平台采用生物製剂、小分子药物和标靶治疗。与远端医疗、远距监测和个人化医疗的整合正在提高治疗的可近性和疗效。人口老化和高风险族群的增加推动了对扩充性、循证解决方案的需求。这些趋势正在推动自体免疫疾病医疗保健生态系统中平台应用的普及。

价格压力和报销限制

生技药品和专科药物需要大量投资，且在管理、监测和支持性护理方面也需要持续投入成本。报销缺口和分散的支付方政策进一步加剧了药物可近性和可负担性的难题。企业在定价模式与临床疗效和病人参与之间寻求平衡方面面临挑战。供应商必须提供基于价值的合约、生物相似药选择以及成本透明的平台，以提高药物的普及率。这些限制因素持续阻碍低收入和无保险族群中此类平台的成熟。

标靶生技药品和小分子药物的进展

为了避免等待时间并提高便利性，患者越来越倾向于选择远距医疗和居家监测。相关平台可连接行动应用、云端基础分析和穿戴式感测器，提供即时洞察和个人化护理。基层医疗、雇主主导的健康计划和保险援助计划对扩充性且符合隐私保护要求的解决方案的需求日益增长。供应商正在提供模组化套件、人工智慧驱动的分流系统和结果仪錶盘，以支援混合护理模式。

竞争与生物相似药的进入

许多地区缺乏训练有素的专业人员、诊断检查室和报销机制，难以支持广泛的筛检和治疗。文化偏见、健康素养低以及数位接取受限进一步降低了需求和参与。企业在向农村和城乡结合部人口部署可扩展、扩充性的解决方案方面面临挑战。供应商必须透过教育宣传活动、行动优先平台以及对公私合营的投资来扩大其覆盖范围。

新冠疫情的影响：

疫情扰乱了全球免疫诊所、诊断流程和治疗顺从性。封锁措施导致面对面就诊延迟，并减少了患者接触专家和输液中心的机会。疫情后的恢復期，自体免疫疾病的治疗重点转向远距远端医疗、数位化诊断和病患自我管理。医疗系统和消费者管道对远端监测、人工智慧筛检和家庭治疗的投资激增。政策制定者和临床医生越来越意识到免疫健康与感染风险以及慢性病管理之间的关联。

预计在预测期内，生技药品领域将占据最大的市场份额。

由于生物製剂在治疗上具有重要意义，且拥有创新开发平臺，并在自体免疫疾病领域展现出临床疗效，预计在预测期内，生技药品领域将占据最大的市场份额。生物製剂平台可支持抗发炎、免疫抑制和标靶干预，可作为传统治疗方法的补充。与个人化医疗、生物标记追踪和联合通讯协定的整合，能够改善治疗效果并优化患者分层。对于慢性或难治性病例，非类固醇类药物和基于精准医疗的治疗方法需求日益增长。供应商提供单株抗体、融合蛋白和细胞激素调节剂，旨在满足自体免疫疾病的特征。

预计在预测期内，发炎性肠道疾病细分市场将呈现最高的复合年增长率。

随着自体免疫平台拓展至消化器官系统和全身发炎管理领域，预计发炎性肠道疾病领域将在预测期内达到最高成长率。克隆氏症和溃疡性大肠炎等疾病的发生率因饮食习惯改变、肠道菌丛失调和遗传易感性而不断上升。该平台有助于追踪症状、预测病情復发，并将胃肠道和免疫学工作流程中的护理整合起来。与远端医疗、穿戴式感测器和患者报告结果的整合，能够改善个人化治疗并提高患者依从性。专科诊所、支付方网路和人群健康计划对扩充性的多学科解决方案的需求日益增长。

占比最大的地区：

由于人口密度高、疾病负担加重以及自体免疫治疗领域的医疗现代化，预计亚太地区将在预测期内占据最大的市场份额。中国、印度、日本和韩国等国家正在都市区医院、企业健康计画和公共卫生计画中拓展平台应用。政府主导的措施正在支持慢性病管理的基础设施建设、数位医疗应用和宣传宣传活动。本地医疗服务提供者正在提供经济高效、符合当地文化且以行动端为先的解决方案，以满足当地需求。都市区和近郊市场对扩充性且整体性的自体免疫疾病基础设施的需求日益增长。

预计年复合成长率最高的地区：

在预测期内，随着自体免疫疾病技术的创新、报销和临床应用不断融合，北美预计将成为复合年增长率最高的地区。各公司正在居家医疗、远端医疗和综合护理网络中部署平台，以改善医疗服务的可近性和治疗效果。对人工智慧诊断、生技药品和数位疗法的投资支持了扩充性和个人化治疗。主要供应商、学术机构和支付方框架的存在正在推动生态系统的成熟和创新。各公司正在将自体免疫疾病策略与基于价值的医疗、慢性病管理和雇主健康目标相协调。这些趋势正在推动北美自体免疫疾病基础设施和治疗平台的区域成长。

免费客製化服务

订阅本报告的用户可从以下免费自订选项中选择一项：

  • 公司简介
    • 对最多三家其他公司进行全面分析
    • 对主要企业进行SWOT分析（最多3家公司）
  • 区域分类
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 基于产品系列、地域覆盖和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 引言

  • 概述
  • 相关利益者
  • 分析范围
  • 分析方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 分析方法
  • 分析材料
    • 原始研究资料
    • 二手研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 介绍
  • 司机
  • 抑制因素
  • 市场机会
  • 威胁
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的感染疾病

第四章 波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代产品的威胁
  • 新参与企业的威胁
  • 公司间的竞争

5. 全球自体免疫疾病药物市场（依药物类别划分）

  • 介绍
  • 免疫抑制剂
  • 抗发炎药
  • 皮质类固醇
  • 非类固醇消炎剂（NSAIDs）
  • 生技药品
    • TNF抑制剂
    • 白细胞介素抑制剂
    • B细胞和T细胞调变器
  • 生物相似药

6. 全球自体免疫疾病药物市场（依适应症划分）

  • 介绍
  • 类风湿性关节炎
  • 银屑病、干癣性关节炎
  • 发炎性肠道疾病（克隆氏症、溃疡性大肠炎）
  • 全身性红斑性狼疮
  • 多发性硬化症
  • 1型糖尿病
  • 僵直性脊椎炎
  • 其他迹象

7. 全球自体免疫疾病药物市场（依给药途径划分）

  • 介绍
  • 口服
  • 注射
  • 静脉

8. 全球自体免疫疾病治疗市场（依通路划分）

  • 介绍
  • 医院药房
  • 零售药房
  • 网路药房
  • 专科诊所

9. 全球自体免疫疾病治疗市场（依最终用户划分）

  • 介绍
  • 医院
  • 诊所
  • 居家医疗
  • 研究和学术机构
  • 其他最终用户

第十章 全球自体免疫疾病治疗市场（按地区划分）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章：主要趋势

  • 合约、商业伙伴关係和合资企业
  • 企业合併（M&A）
  • 新产品发布
  • 业务拓展
  • 其他关键策略

第十一章：公司简介

  • AbbVie Inc.
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • Eli Lilly and Company
  • Takeda Pharmaceutical Company Limited
  • UCB SA
  • Biogen Inc.
  • Gilead Sciences Inc.
  • AstraZeneca PLC
  • Merck & Co., Inc.
Product Code: SMRC32187

According to Stratistics MRC, the Global Autoimmune Disease Therapeutics Market is accounted for $7.1 billion in 2025 and is expected to reach $13.6 billion by 2032 growing at a CAGR of 9.6% during the forecast period. Autoimmune Disease Therapeutics refers to treatments designed to manage and alleviate conditions in which the immune system mistakenly attacks the body's own healthy tissues. These therapeutics aim to suppress abnormal immune responses, reduce inflammation, and prevent further tissue damage. They include drugs such as corticosteroids, immunosuppressants, biologics, and targeted therapies that modulate specific immune pathways. Autoimmune disease therapeutics are used to treat disorders like rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease. Ongoing research focuses on developing safer, more effective, and personalized treatments that restore immune balance without compromising the body's defense against infections.

Market Dynamics:

Driver:

Rising disease prevalence & diagnosis rates

Autoimmune conditions are increasing globally due to genetic predisposition environmental triggers and lifestyle factors. Platforms support immunomodulation symptom control and disease progression management using biologics small molecules and targeted therapies. Integration with telehealth remote monitoring and personalized medicine enhances accessibility and treatment outcomes. Demand for scalable and evidence-based solutions is rising across aging populations and high-risk cohorts. These dynamics are propelling platform deployment across autoimmune-focused care ecosystems.

Restraint:

Pricing pressure & reimbursement limits

Biologics and specialty drugs require significant investment and recurring expenses for administration monitoring and supportive care. Reimbursement gaps and fragmented payer policies further complicate access and affordability. Enterprises face challenges in aligning pricing models with clinical outcomes and patient engagement. Vendors must offer value-based contracts biosimilar options and cost-transparent platforms to improve uptake. These constraints continue to hinder platform maturity across low-income and underinsured populations.

Opportunity:

Advances in targeted biologics & small molecules

Patients increasingly prefer virtual consultations and home-based monitoring to avoid clinical wait times and improve convenience. Platforms integrate with mobile apps cloud-based analytics and wearable sensors to deliver real-time insights and personalized therapy. Demand for scalable and privacy-compliant solutions is rising across primary care employer wellness and insurance-backed programs. Vendors offer modular kits AI-driven triage and outcome dashboards to support hybrid care models.

Threat:

Competition and biosimilar entry

Many regions lack trained specialists diagnostic labs and reimbursement frameworks to support widespread screening and treatment. Cultural stigma low health literacy and limited digital access further degrade demand and engagement. Enterprises face challenges in deploying scalable and regionally adapted solutions across rural and peri-urban populations. Vendors must invest in education campaigns mobile-first platforms and public-private partnerships to expand reach.

Covid-19 Impact:

The pandemic disrupted immunology clinics diagnostic workflows and therapy adherence across global markets. Lockdowns delayed in-person visits and reduced access to specialists and infusion centers. Post-pandemic recovery emphasized remote care digital diagnostics and patient self-management across autoimmune medicine. Investment in telemonitoring AI screening and home-based therapy surged across healthcare systems and consumer channels. Public awareness of immune health and its link to infection risk and chronic disease management increased across policy and clinical circles.

The biologics segment is expected to be the largest during the forecast period

The biologics segment is expected to account for the largest market share during the forecast period due to its therapeutic relevance, innovation pipeline, and clinical efficacy across autoimmune conditions. Platforms support anti-inflammatory, immunosuppressive, and targeted interventions that complement conventional therapies. Integration with personalized medicine, biomarker tracking, and combination protocols enhances treatment outcomes and patient stratification. Demand for non-steroidal and precision-driven options is rising across chronic and refractory cases. Vendors offer monoclonal antibodies, fusion proteins, and cytokine modulators tailored to autoimmune disease profiles.

The inflammatory bowel disease segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the inflammatory bowel disease segment is predicted to witness the highest growth rate as autoimmune platforms expand across gastrointestinal and systemic inflammation management. Conditions such as Crohn's disease and ulcerative colitis are increasing due to dietary shifts, microbiome disruption, and genetic susceptibility. Platforms support symptom tracking, flare prediction, and integrated care across gastroenterology and immunology workflows. Integration with telehealth, wearable sensors, and patient-reported outcomes enhances personalization and adherence. Demand for scalable and cross-specialty solutions is rising across specialty clinics, payer networks, and public health programs.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its population density, rising disease burden, and healthcare modernization across autoimmune medicine. Countries like China, India, Japan, and South Korea scale platforms across urban hospitals, employer wellness, and public health programs. Government-backed initiatives support infrastructure development, digital health adoption, and awareness campaigns across chronic disease management. Local providers offer cost-effective, culturally adapted, and mobile-first solutions tailored to regional needs. Demand for scalable and inclusive autoimmune infrastructure is rising across urban and peri-urban markets.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR as innovation, reimbursement, and clinical adoption converge across autoimmune disease technologies. Enterprises deploy platforms across homecare, telehealth, and integrated care networks to improve access and outcomes. Investment in AI diagnostics, biologics, and digital therapeutics supports scalability and personalization. Presence of leading vendors, academic institutions, and payer frameworks drives ecosystem maturity and innovation. Firms align autoimmune strategies with value-based care, chronic disease management, and employer wellness goals. These trends are accelerating regional growth across North America's autoimmune disease infrastructure and therapeutic platforms.

Key players in the market

Some of the key players in Autoimmune Disease Therapeutics Market include AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Sanofi S.A., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, UCB S.A., Biogen Inc., Gilead Sciences Inc., AstraZeneca PLC and Merck & Co., Inc.

Key Developments:

In June 2025, AbbVie announced a definitive agreement to acquire Capstan Therapeutics for up to $2.1 billion, and completed the transaction. Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) delivering mRNA encoding anti-CD19 CAR to CD8+ T cells. The acquisition added a potential first-in-class therapy for B cell-mediated autoimmune diseases, aiming for durable, drug-free remission.

In October 2023, Amgen completed the $27.8 billion acquisition of Horizon Therapeutics plc, gaining access to first-in-class therapies for rare autoimmune diseases. The deal added Tepezza (thyroid eye disease) and Krystexxa (chronic gout) to Amgen's portfolio, significantly expanding its reach in immunology and inflammation markets.

Drug Classes Covered:

  • Immunosuppressants
  • Anti-inflammatory Drugs
  • Corticosteroids
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Biologics
  • Biosimilars

Indications Covered:

  • Rheumatoid Arthritis
  • Psoriasis & Psoriatic Arthritis
  • Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis)
  • Systemic Lupus Erythematosus
  • Multiple Sclerosis
  • Type 1 Diabetes
  • Ankylosing Spondylitis
  • Other Indications

Route of Administrations Covered:

  • Oral
  • Injectable
  • Intravenous

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics

End Users Covered:

  • Hospitals
  • Clinics
  • Homecare Settings
  • Research & Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Autoimmune Disease Therapeutics Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Immunosuppressants
  • 5.3 Anti-inflammatory Drugs
  • 5.4 Corticosteroids
  • 5.5 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • 5.6 Biologics
    • 5.6.1 TNF Inhibitors
    • 5.6.2 Interleukin Inhibitors
    • 5.6.3 B-cell and T-cell Modulators
  • 5.7 Biosimilars

6 Global Autoimmune Disease Therapeutics Market, By Indication

  • 6.1 Introduction
  • 6.2 Rheumatoid Arthritis
  • 6.3 Psoriasis & Psoriatic Arthritis
  • 6.4 Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis)
  • 6.5 Systemic Lupus Erythematosus
  • 6.6 Multiple Sclerosis
  • 6.7 Type 1 Diabetes
  • 6.8 Ankylosing Spondylitis
  • 6.9 Other Indications

7 Global Autoimmune Disease Therapeutics Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Injectable
  • 7.4 Intravenous

8 Global Autoimmune Disease Therapeutics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Specialty Clinics

9 Global Autoimmune Disease Therapeutics Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Homecare Settings
  • 9.5 Research & Academic Institutes
  • 9.6 Other End Users

10 Global Autoimmune Disease Therapeutics Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AbbVie Inc.
  • 12.2 Johnson & Johnson Services Inc.
  • 12.3 Pfizer Inc.
  • 12.4 Amgen Inc.
  • 12.5 Novartis AG
  • 12.6 F. Hoffmann-La Roche Ltd.
  • 12.7 Bristol-Myers Squibb Company
  • 12.8 Sanofi S.A.
  • 12.9 Eli Lilly and Company
  • 12.10 Takeda Pharmaceutical Company Limited
  • 12.11 UCB S.A.
  • 12.12 Biogen Inc.
  • 12.13 Gilead Sciences Inc.
  • 12.14 AstraZeneca PLC
  • 12.15 Merck & Co., Inc.

List of Tables

  • Table 1 Global Autoimmune Disease Therapeutics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Autoimmune Disease Therapeutics Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 3 Global Autoimmune Disease Therapeutics Market Outlook, By Immunosuppressants (2024-2032) ($MN)
  • Table 4 Global Autoimmune Disease Therapeutics Market Outlook, By Anti-inflammatory Drugs (2024-2032) ($MN)
  • Table 5 Global Autoimmune Disease Therapeutics Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 6 Global Autoimmune Disease Therapeutics Market Outlook, By Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (2024-2032) ($MN)
  • Table 7 Global Autoimmune Disease Therapeutics Market Outlook, By Biologics (2024-2032) ($MN)
  • Table 8 Global Autoimmune Disease Therapeutics Market Outlook, By TNF Inhibitors (2024-2032) ($MN)
  • Table 9 Global Autoimmune Disease Therapeutics Market Outlook, By Interleukin Inhibitors (2024-2032) ($MN)
  • Table 10 Global Autoimmune Disease Therapeutics Market Outlook, By B-cell and T-cell Modulators (2024-2032) ($MN)
  • Table 11 Global Autoimmune Disease Therapeutics Market Outlook, By Biosimilars (2024-2032) ($MN)
  • Table 12 Global Autoimmune Disease Therapeutics Market Outlook, By Indication (2024-2032) ($MN)
  • Table 13 Global Autoimmune Disease Therapeutics Market Outlook, By Rheumatoid Arthritis (2024-2032) ($MN)
  • Table 14 Global Autoimmune Disease Therapeutics Market Outlook, By Psoriasis & Psoriatic Arthritis (2024-2032) ($MN)
  • Table 15 Global Autoimmune Disease Therapeutics Market Outlook, By Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis) (2024-2032) ($MN)
  • Table 16 Global Autoimmune Disease Therapeutics Market Outlook, By Systemic Lupus Erythematosus (2024-2032) ($MN)
  • Table 17 Global Autoimmune Disease Therapeutics Market Outlook, By Multiple Sclerosis (2024-2032) ($MN)
  • Table 18 Global Autoimmune Disease Therapeutics Market Outlook, By Type 1 Diabetes (2024-2032) ($MN)
  • Table 19 Global Autoimmune Disease Therapeutics Market Outlook, By Ankylosing Spondylitis (2024-2032) ($MN)
  • Table 20 Global Autoimmune Disease Therapeutics Market Outlook, By Other Indications (2024-2032) ($MN)
  • Table 21 Global Autoimmune Disease Therapeutics Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 22 Global Autoimmune Disease Therapeutics Market Outlook, By Oral (2024-2032) ($MN)
  • Table 23 Global Autoimmune Disease Therapeutics Market Outlook, By Injectable (2024-2032) ($MN)
  • Table 24 Global Autoimmune Disease Therapeutics Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 25 Global Autoimmune Disease Therapeutics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 26 Global Autoimmune Disease Therapeutics Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 27 Global Autoimmune Disease Therapeutics Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 28 Global Autoimmune Disease Therapeutics Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 29 Global Autoimmune Disease Therapeutics Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 30 Global Autoimmune Disease Therapeutics Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Autoimmune Disease Therapeutics Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 32 Global Autoimmune Disease Therapeutics Market Outlook, By Clinics (2024-2032) ($MN)
  • Table 33 Global Autoimmune Disease Therapeutics Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 34 Global Autoimmune Disease Therapeutics Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 35 Global Autoimmune Disease Therapeutics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.